Alida Biosciences raised $7.5M in a Series A funding led by Genoa Ventures and Early Access Launch of Innovative Products for Epitranscriptomic Research

Alida Biosciences has successfully completed a $7.5 million Series A funding round led by Genoa Ventures, with participation from FusionX Ventures and Vertical Venture Partners. The funding is complemented by two ongoing SBIR grants totaling $4 million from The National Human Genome Research Institute (NHGRI). In addition, AlidaBio has unveiled the Early Access launch of two products: the EpiPlex™ RNA Library Prep Kit and the EpiScout™ Analysis Suite.